Statin + fibrate combination therapy: Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease

摘要: We evaluated the use of combination therapy (ciprofibrate 100 mg or bezafibrate 400 plus fluvastatin 40 mg) in 23 patients (n=13 ciprofibrate group) with established cardiovascular disease. Both treatments achieved a significant (P less than equal to 0.01) decrease total cholesterol (TC) (32 and 21%), triglycerides (TG) (53 46%) low-density lipoprotein (LDL) (36 26%) levels TC/high-density Lipoprotein (HDL) (42 31%) LDL/HDL (46 35%) ratios. HDL were increased (19% for both treatment groups), but this rise only significance (P=0.01) group. Although two patient groups not strictly matched, reduction serum TC LDL was greater 36%, respectively; P 0.001) (21 26%, 0.01). There plasma fibrinogen (36.4 13.5% group, respectively). None reported myalgia had abnormal creatine kinase activity liver function tests. Combination is worth considering high-risk because advantages associated option, competitively priced when compared high doses statins. An end-point-based trial needed. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.